Trial results

A Study of Cardiovascular Events iN Diabetes Plus

NCT05441267 on ClinicalTrials.gov · last registry update 2026-06-23

An unusually large phase 4: 21,296 participants, more than double the 72 typical for the stage. Due to report 17 August 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 13 March 2023 — 3 years so far. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P4

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

University of Oxford

Sponsor type

Other

Enrollment

21,296

Started

2023-03-13

Primary completion

2028-08-17 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.